Specialty pharmacies can play an integral part in supporting patients during these times of uncertainty.
Recommendations for optimizing success on treatment for patients with chronic lymphocytic leukemia (CLL).
How MRD (minimum residual disease) testing affects the use of limited duration therapy
Trials focusing on patient populations with newly diagnosed chronic lymphocytic leukemia (CLL).
A comparison of the safety and efficacy of orally and intravenously administered oncolytics.
Which characteristics of oral therapies need to be managed by pharmacists.
Targeting excessive host inflammation with a BTK inhibitor is a therapeutic strategy in severe COVID-19
A thank you message to all of our providers.